Scholarlink

Background <p>Most patients with intrahepatic cholangiocarcinoma (ICC) are diagnosed at advanced stages and are thus ineligible for surgery. Recently, a combination of immunotherapy, chemotherapy, and lenvatinib has shown promising results for treating advanced ICC.<sup><CitationRef AdditionalCitationIDS="CR2 CR3" CitationID="CR1">1–3</CitationRef></sup> Laparoscopic anatomical liver resection of segment 8 remains challenging.<sup><CitationRef AdditionalCitationIDS="CR5" CitationID="CR4">4,5</CitationRef></sup> We present a case of advanced ICC treated with durvalumab, gemcitabine plus oxaliplatin (GEMOX), and lenvatinib, followed by laparoscopic extended segmentectomy 8 using indocyanine green (ICG) fluorescent staining.</p> Methods <p>A 54-year-old patient was found to have a hepatic tumor in segment 8, with invasion into the right hepatic vein and multiple enlarged lymph nodes, confirmed by abdominal computed tomography (CT). After six cycles of conversion therapy, partial response was achieved. The patient then underwent laparoscopic extended segmentectomy 8 and right hepatic vein resection. Preoperative planning with three-dimensional (3D) reconstruction, along with intraoperative ultrasonography and ICG-guided fluorescent staining, greatly enhanced the precision and success of the surgery.</p> Results <p>The operation lasted 220&#xa0;min with an estimated blood loss of 800&#xa0;mL. The Pringle maneuver was performed intermittently six times for a total of 85&#xa0;min. The patient was discharged on the 12th postoperative day without complications. Postoperatively, the patient received adjuvant therapy with durvalumab and capecitabine, <sup><CitationRef CitationID="CR6">6</CitationRef></sup> achieving recurrence-free survival for over 6&#xa0;months.</p> Conclusions <p>Cases of patients with advanced ICC undergoing surgical resection after immunotherapy and chemotherapy are rare. The combination of GEMOX, durvalumab, and lenvatinib showed promising antitumor efficacy and safety, suggesting its potential as a feasible and safe conversion therapy for advanced ICC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Laparoscopic Extended Segmentectomy 8 with Right Hepatic Vein Resection After Conversion Therapy for Advanced Intrahepatic Cholangiocarcinoma

  • 期刊论文

  • 发表日期：

    2025年5月21日

查看全文
  • Wenliang Tan,
  • Jinxing Wei,
  • Yajin Chen,
  • Changzhen Shang

摘要

Background

Most patients with intrahepatic cholangiocarcinoma (ICC) are diagnosed at advanced stages and are thus ineligible for surgery. Recently, a combination of immunotherapy, chemotherapy, and lenvatinib has shown promising results for treating advanced ICC.1–3 Laparoscopic anatomical liver resection of segment 8 remains challenging.4,5 We present a case of advanced ICC treated with durvalumab, gemcitabine plus oxaliplatin (GEMOX), and lenvatinib, followed by laparoscopic extended segmentectomy 8 using indocyanine green (ICG) fluorescent staining.

Methods

A 54-year-old patient was found to have a hepatic tumor in segment 8, with invasion into the right hepatic vein and multiple enlarged lymph nodes, confirmed by abdominal computed tomography (CT). After six cycles of conversion therapy, partial response was achieved. The patient then underwent laparoscopic extended segmentectomy 8 and right hepatic vein resection. Preoperative planning with three-dimensional (3D) reconstruction, along with intraoperative ultrasonography and ICG-guided fluorescent staining, greatly enhanced the precision and success of the surgery.

Results

The operation lasted 220 min with an estimated blood loss of 800 mL. The Pringle maneuver was performed intermittently six times for a total of 85 min. The patient was discharged on the 12th postoperative day without complications. Postoperatively, the patient received adjuvant therapy with durvalumab and capecitabine, 6 achieving recurrence-free survival for over 6 months.

Conclusions

Cases of patients with advanced ICC undergoing surgical resection after immunotherapy and chemotherapy are rare. The combination of GEMOX, durvalumab, and lenvatinib showed promising antitumor efficacy and safety, suggesting its potential as a feasible and safe conversion therapy for advanced ICC.